Ion channels continue to be an important therapeutic target for a range of indications such as hypertension, arrhythmia, pain, stroke, epilepsy, depression, diabetes, local anesthesia, bipolar disorder, COPD, and autoimmune disorders. Ion channels are not only important drug targets, but also play an important role in drug safety evaluation. Many drugs withdrawn from the market due to cardiac-related side effects have been shown to block the human ether-a-go-go (hERG) ion channel, delaying repolarization of the cardiac action potential and possibly leading to a potentially fatal arrhythmia.
The success of any ion channel research program involves complex decisions that require specific expertise to address the complexities of these difficult biological targets. At Creative Bioarray, we have a team dedicated to helping you identify these choices, and we can work with you from determining the right detection format (binding and/or functional) and platform up to the data interpretation. From single-cell manual patch clamp (the gold standard) to high-throughput 384-well automated electrophysiological instruments, we have the capabilities to utilize platforms and strategies to deliver the throughput, results, and depth of analysis to meet your needs.
|Types of Diseases||Available Target Panels||Screening Capabilities|
|Ion channel||Cardiac safety|
|Cancer||Cav3.3||Cav1.2||Radioligand binding assay|
|Cardiac||HCN2||hERG||Ion flux assay|
|Neurodegeneration/Stroke||Kv3.1||Kir3.1/Kir3/4||Cardiac safety and function assays|
For more information on ion channel screening services, please contact us.